Immunosuppressive Tryptophan Catabolism and Gut Mucosal Dysfunction Following Early HIV Infection

Journal of Infectious Diseases

Volumn 212, Issue 3, 2015, Pages 355-366

  Jenabian, Mohammad Ali ^a,b,l   El Far, Mohamed ^e   Vyboh, Kishanda ^a,b   Kema, Ido ^k   Costiniuk, Cecilia T ^a,c   Thomas, Rejean ^f   Baril, Jean Guy ^g   Leblanc, Roger ^a,h   Kanagaratham, Cynthia ^b   Radzioch, Danuta ^b   Allam, Ossama ^i,j   Ahmad, Ali ^i,j   Lebouché, Bertrand ^a   Tremblay, Cécile ^e,i   Ancuta, Petronela ^e,i   Routy, Jean Pierre ^a,b,d  

^a Chronic Viral Illness Service   (Canada)

^b HYDRO QUÉBEC   (Canada)

^c Division of Infectious Diseases   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Clinique Medicale l'Actuel   (Canada)

^g Clinique Médicale Quartier Latin   (Canada)

^h Clinique Médicale OPUS   (Canada)

ⁱ Department of Microbiology and Immunology ^*  (Canada)

^j UNIVERSITY OF MONTREAL   (Canada)

^k UNIVERSITY OF GRONINGEN   (Netherlands)

^l UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

more..

Author keywords

ART; dendritic cells; gut mucosal dysfunction; HIV early infection; indoleamine 2,3 dioxygenase 1 (IDO 1); inflammation; microbial translocation; regulatory T cells (Tregs); sST2; tryptophan

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FATTY ACID BINDING PROTEIN 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; KYNURENINE; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; SOLUBLE SUPPRESSION OF TUMORIGENICITY 2; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AMINO ACID METABOLISM; CATABOLISM; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EARLY INTERVENTION; ENTEROPATHY; FEMALE; GUT MUCOSAL DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; AGED; HIV INFECTIONS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; DENDRITIC CELLS; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; KYNURENINE; LONGITUDINAL STUDIES; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN;

EID: 84936810525     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv037     Document Type: Conference Paper

References (50)

1. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384:258-71.
2. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-45.
3. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-66.
4. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32ra6.
5. Jenabian MA, Patel M, Kema I, et al. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One 2013; 8:e78146.
6. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34:137-43.
7. Zhu BT. Development of selective immune tolerance towards the allogeneic fetus during pregnancy: Role of tryptophan catabolites (Review). Int J Mol Med 2010; 25:831-5.
8. Fuchs D, Moller AA, Reibnegger G, et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 1991; 28:207-11.
9. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis 2014; 210:128-38.
10. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91.
11. Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: The randomized Primo-SHM trial. PLoS Med 2012; 9:e1001196.
12. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
13. Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012; 17:1001-9.
14. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012; 109:9523-8.
15. Adalid-Peralta L, Grangeot-Keros L, Rudent A, et al. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med 2006; 7:514-9.
16. Grijsen M, Koster G, van Vonderen M, et al. Temporary antiretroviral treatment during primary HIV-1 infection has a positive impact on health-related quality of life: data from the Primo-SHM cohort study. HIV Med 2012; 13:630-5.
17. Zangerle R, Widner B, Quirchmair G, Neurauter G, Sarcletti M, Fuchs D. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. Clin Immunol 2002; 104:242-7.
18. Chen J, Shao J, Cai R, et al. Anti-retroviral therapy decreases but does not normalize indoleamine 2,3-dioxygenase activity in HIV-infected patients. PLoS One 2014; 9:e100446.
19. Jenabian MA, Patel M, Kema I, et al. Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. Clin Exp Immunol 2014; 178:102-11.
20. Tsoukas C. Immunosenescence and aging in HIV. Curr Opin HIVAIDS 2014; 9:398-404.
21. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10: e1004078.
22. Lehmann C, Jung N, Forster K, et al. Longitudinal analysis of distribution and function of plasmacytoid dendritic cells in peripheral blood and gut mucosa of HIV infected patients. J Infect Dis 2014; 209:940-9.
23. Zelante T, Iannitti RG, Cunha C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39:372-85.
24. Kader M,Wang X, Piatak M, et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009; 2:439-49.
25. Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 2013; 9:e1003453.
26. Diaz-Jimenez D, Nunez LE, Beltran CJ, et al. Soluble ST2: A new and promising activity marker in ulcerative colitis. World J Gastroenterol 2011; 17:2181-90.
27. Miyagaki T, Sugaya M, Yokobayashi H, et al. High levels of soluble ST2 and low levels of IL-33 in sera of patients with HIV infection. J Invest Dermatol 2011; 131:794-6.
28. Pastorelli L, De Salvo C, Vecchi M, Pizarro TT. The role of IL-33 in gut mucosal inflammation. Mediators Inflamm 2013; 2013:608187.
29. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008; 3:e2516.
30. Hunt PW, Sinclair E, Rodriguez B, et al. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J Infect Dis 2014; 210:1228-38.
31. Byakwaga H, Boum Y II, Huang Y, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis 2014; 210:383-91.
32. Liovat AS, Rey-Cuille MA, Lecuroux C, et al. Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One 2012; 7:e46143.
33. Leeansyah E, Malone DF, Anthony DD, Sandberg JK. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 2013; 8:117-24.
34. Le Floc'h N, OttenW, Merlot E. Tryptophan metabolism, from nutrition to potential therapeutic applications. Amino Acids 2011; 41:1195-205.
35. Costiniuk CT, Angel JB. Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol 2012; 5:596-604.
36. Veazey RS, Tham IC, Mansfield KG, et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol 2000; 74:57-64.
37. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006; 3:e484.
38. Zeng M, Smith AJ,Wietgrefe SW, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest 2011; 121:998-1008.
39. Vreugdenhil AC, Wolters VM, Adriaanse MP, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scand J Gastroenterol 2011; 46:1435-41.
40. Adriaanse MP, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther 2013; 37:482-90.
41. Asmuth DM, Ma ZM, Albanese A, et al. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS 2013; 27:2207-17.
42. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-90.
43. Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013; 369:529-39.
44. Verhasselt V, Buelens C, Willems F, De Groote D, Haeffner-Cavaillon N, Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J Immunol 1997; 158:2919-25.
45. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
46. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761-70.
47. Kok A, Hocqueloux L, Hocini H, et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIVinfected patients. Mucosal Immunol 2015; 8:127-40.
48. Balmer ML, Slack E, de Gottardi A, et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med 2014; 6:237ra66.
49. WoodNJ. Liver: The liver as a firewall-clearance of commensal bacteria that have escaped from the gut. Nat Rev Gastroenterol Hepatol 2014; 11:391.
50. Sereti I, Estes JD, Thompson WL, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 2014; 10:e1003890.